Loading
TechnoGenesys makes (R)-9b, a tablet that blocks a protein called ACK1 which helps prostate cancer keep using male hormones after standard hormone drugs stop working. It is in a first trial in men with advanced prostate cancer.
TechnoGenesys, Inc., of St. Louis, Missouri, is commercialising (R)-9b, which it calls mahatinib, a small-molecule inhibitor of the androgen receptor-interacting tyrosine kinase ACK1 (TNK2). The company says ACK1 inhibition suppresses androgen receptor and AR-V7 expression, that (R)-9b resensitises enzalutamide- and abiraterone-resistant prostate cancer in preclinical work, and that it also promotes CD8 T-cell responses. The PHAROS phase 1 trial (NCT06705686, IND 167907) is the first clinical test of an ACK1 inhibitor, in metastatic castration-resistant prostate cancer. The company also names triple-negative breast and non-small cell lung cancer as later indications. Its first registered cancer trial, NCT06705686, was posted on ClinicalTrials.gov in November 2024.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/